Board of Directors
Rick E. Winningham, Chair
Chairman and CEO, Theravance Biopharma, Inc.
Harold E. Van Wart, Ph.D. Vice Chair
President and Chief Executive Officer, Cymabay
Bruce W. Jenett, Secretary
Senior Counsel, DLA Piper LLP (US)
Steve E. Krognes, Treasurer
Chief Financial Officer, Pharma North America, Genentech, Inc.
Jeffrey Bluestone, PhD
A.W. And Mary Margaret Distinguished Professor, CEO and President of the Institute for Cancer Immunotherapy, University of California, San Francisco
Donald E. Bobo, Jr.
Corporate Vice President, Corporate Strategy & Development, General Manager Heart Valve Therapy Edwards Lifesciences
Mark D. Carlson, M.D., M.A.
Vice President Global Clinical Affairs and Chief Medical Officer, St. Jude Medical, Inc.
Kenneth E. Drazan M.D.
Head Johnson & Johnson Innovation, Johnson & Johnson - California Innovation Center
Kristen M. Hege, M.D.
San Francisco Site Head and Vice President, Translational Development, Hematology & Oncology Celgene
Terry Hermiston, Ph.D.
Vice President, Biologics Research, U.S. Innovation Center Site Head, Bayer HealthCare Pharmaceuticals
Shlomo Melmed M.D., M.D., F.R.C.
Senior Vice President for Academic Affairs, Chief Academic Officer and Dean of the Medical Faculty Cedars-Sinai Health System
Maulik Nanavaty, Ph.D., M.B.A.
Senior Vice President and President, Neuromodulation Division, Boston Scientific - Neuromodulation
Stephanie Okey M.S.
Head of North America, Rare Diseases Senior Vice President, General Manager, US Rare Disease, Genzyme Corporation
Senior Vice President and President, Aortic and Peripheral Vascular, Medtronic CardioVascular (Santa Rosa)